Latest News

Maze Therapeutics debuts on Nasdaq with a lukewarm $690.4 Million valuation

Maze Therapeutics was the latest drug-developer to list on the New York Stock Exchange. Its shares rose nearly 1% during their debut and gave the company a value of $690.37 millions.

The market's muted reaction indicates that investors are still cautious, as the demand for new listings is slowly recovering after a dry spell of nearly three years.

The opening price for the company's shares was $16.12, compared to an initial public offering of $16.

Maze increased its IPO size to 8.75 million shares in the range of $15-$17 each, to raise $140 millions. It originally planned to sell 7.8 million share.

Maze develops drugs to treat chronic renal diseases. Two of the leading experimental candidates are MZE829 in a midstage study and MZE782 in an early stage study. Initial data is expected in 2025's second half.

Last month, Maze raised $115 million through a Series-D round led by Frazier and Deep Track Capital.

HEALTHCARE IPO PIPELINE

Many healthcare companies are eager to test out the IPO market. Medline is at the top of the list, having filed confidentially for an IPO which could value it up to $50 billion.

According to an EY report, healthcare companies will dominate IPO listings by 2024, accounting for 43% of the volume and 26% in value of deals exceeding $50 million.

Despite their stellar debuts, the market response has been tepid. Weight-loss drug developers BioAge and MBX Biosciences are both trading well below their IPO price, according to LSEG data.

The recent healthcare IPO performance was subdued due to post-election uncertainties. This may eventually resolve, but it is clearly affecting investor confidence for the time being," said Dr. Lukas Mühlbauer from IPOX Schuster.

(source: Reuters)